Ottawa, ON / Business Wire / August 20, 2019 / – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance, is pleased to announce that it has received approval for OxC-beta™ Livestock (“OxC-beta”) in Mexico. The application, for broiler hens and pigs, was approved by SADER (formally known as SAGARPA) in conjunction with the Mexican General Office for Animal Health, Office of Livestock Services and Certification.
With a population of 132.5 million people, Mexico consumes approximately 35mm tons of feed annually, of which the broiler and pig market constitutes approximately 16mm tons, ranking them sixth globally in feed consumption behind China, the United States, Brazil, Russia and India[i].
In conjunction with this approval and to help expedite the sales process, Avivagen also announces that it will be working with Meyenberg International Group, a well known and established marketing consulting firm based in Guadalajara, Mexico. With a clientele predominantly from North America, Meyenberg’s vast experience within the region helps its clients to establish and expand sales throughout Mexico and Latin America.
“We are very excited about the approval of OxC-beta™ Livestock in Mexico, as it not only continues to demonstrate the expanding validation of our product world wide, but now allows Avivagen to sell our product in a second large market within North America”, said Mr. Kym Anthony, Avivagen’s CEO. “With our JV partnership already established in the U.S. with CSA Animal Nutrition and numerous confirmatory trials currently under way with large potential U.S. customers, we are very excited about the future growth of our company”.
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.
About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colours, and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds. OxC-beta™ Livestock is currently registered and available for sale in the United States, Philippines, Taiwan, New Zealand and Thailand.
Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements regarding the potential for sale of OxC-beta Livestock in Mexico, the U.S. or other markets, the potential for consultants to assist in achieving sales, the future growth of Avivagen, and the potential for OxC-beta™ Livestock to fulfill the global mandate to remove all in-feed antibiotics as growth promoters are forward looking statements. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications, Avivagen may not grow as anticipated or at all and Avivagen’s products may not be widely accepted as a replacement for antibiotics in livestock feeds due to many factors, many of which are outside of Avivagen’s control. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information:
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164
[i] 2019 Alltech Global Feed Survey